Saturday, October 31, 2026

EUR/CHF Is 2% Up In The Last 21 Sessions

EUR/CHF Is 2% Up In The Last 21 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 2.5% for the last 21 sessions. At 20:06 EST on Wednesday, 27 March, EUR/CHF (EURCHF) is $0.98.

EUR/CHF's yearly highs and lows, it's 8.483% up from its 52-week low and 1.942% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was 0.08%, 0.07%, and 0.24%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.51% (last week), 0.23% (last month), and 0.24% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy: the next major technical resistance after the 151.95-152.00 zone is not before 160.00 – BBH. According to FXStreet on Wednesday, 27 March, "In our view, it's only a matter of time before USD/JPY breaks higher because we anticipate a gradual BoJ tightening process and a more muted than currently priced-in Fed easing cycle.", "The next major technical resistance for USD/JPY after the 151.95-152.00 zone is not before 160.00 (April 1990 high)."
  • According to FXStreet on Tuesday, 26 March, "The declining FX volatility may keep the Japanese Yen pressured by funding demand for carry trades, making USD/JPY even more reliant on a move in USD rates, economists at ING say.", "Our call remains bearish on USD/JPY moving forward, but in the very short term, the pair may retest the 152.00+ 'verbal intervention' area."
  • According to FXStreet on Wednesday, 27 March, "His reaction comes in response to the USD/JPY pair climbing to a fresh 34-year high of 151.97.", "Following his comments, USD/JPY corrected sharply to near 151.70, still up 0.11% on the day."
  • According to FXStreet on Wednesday, 27 March, "Given that oscillators on the daily chart are holding comfortably in the positive territory, the USD/JPY pair might then prolong its well-established uptrend witnessed since January 2023 and climb further towards the 153.00 round figure.", "This is closely followed by the 150.00 psychological mark, which, if broken decisively, could make the USD/JPY pair vulnerable to accelerate the corrective decline further towards the 149.35-149.30 region en route to the 149.00 mark."
  • According to FXStreet on Wednesday, 27 March, "The Japanese Yen (JPY) continued to weaken against the US Dollar (USD), with USD/JPY reaching its highest level since 1990 near 152.00 early Wednesday. ", "After coming within a few pips of 152.00, USD/JPY edged slightly lower but stabilized above 151.50."

More news about EUR/CHF (EURCHF).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com